C0009402||Colorectal Choriocarcinoma
C2931459||Lynch Syndrome
C0087111||therapy
C1527249||colorectal cancer
C1513380||molecular analysis
C0032961||extra-gestational
C0009402||colorectal choriocarcinoma
C2931459||Lynch syndrome
C0262926||history of
C0024623||gastric cancer
C0677898||invasive tumor
C1305188||right hemicolon
C0494165||liver metastasis
C0192861||right hemicolectomy
C0041182||mixed trophoblastic
C1135936||syncytiotrophoblastic
C0008497||choriocarcinoma
C0242656||Disease progression
C0069717||oxaliplatin
C0671970||capecitabine
C0123931||irinotecan
C0796392||bevacizumab
C1285572||Molecular phenotyping
C1333235||mismatch-repair protein
C0487602||immunostaining
C1333235||PMS2
C0920269||microsatellite instability
C1511021||BRAF mutation
C2931459||Lynch syndrome
C3711796||ataxia telangiectasia mutated (p.P604S)
C0599155||missense mutation
C0005740||bleomycin
C0015133||etoposide
C0008838||cisplatin
C0040808||treatment protocol
C4021985||germ cell neoplasia
C0544452||disease remission
C0393006||genetic testing
C4054123||uncommon cancers
C2931459||Lynch syndrome
C4054123||rare tumors
C0087111||therapeutic approaches